ALBANY

AMRI CFO to Present at 2012 Wells Fargo Securities Healthcare Conference

14:05 12.06.12

PR Newswire

ALBANY, N.Y., June 12, 2012

ALBANY, N.Y., June 12, 2012 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that AMRI Senior Vice President, Administration and Chief Financial Officer Mark T. Frost will present at the 2012 Wells Fargo Securities Healthcare Conference on Tuesday, June 19, 2012 at 9:30 a.m. ET.

(Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO)

An audio webcast of the corporate presentation will be available to investors and interested parties by accessing the company's website at www.amriglobal.com. This webcast will be archived for 90 days following the live presentation.

About AMRI

Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development, and manufacturing services. For over 21 years AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development.  

SOURCE AMRI
Quelle: PR Newswire  

http://www.ariva.de/news/...s-Discovery-Capabilities-in-India-4142792  

frisch aus dem Depot kopiert  

Soll ich's reinkopieren oder reicht Ihnen das Anklicken?
Wir erfüllen Ihnen jeden erdenklichen Wunsch.
Einfach an der Lampe rubbeln und Aladin und Buran stehen Ihnen zur Verfügung,Herr.

rt+3,00% da lächst das Zockerherz ;-))))  

das Pushen  

schraubt sich jetzt hoch,mal den SK abwarten heute *grinz*  

>> 0,37% !  

13.07.12 2,70 2,70 2,62 2,68 $ 28.422 76 T
  12.07.12      2,75      2,77§2,67 2,67 $ 49.080 134 T
  11.07.12    2,6572      2,76§2,6501 2,76 $ 18.699 51 T
  10.07.12      2,81      2,81§2,64 2,66 $ 80.220 216 T
  09.07.12      2,67      2,79§2,67 2,78 $ 54.717 149 T
  06.07.12      2,69      2,72§2,65 2,71 $ 37.391 101 T
  05.07.12      2,75      2,80§2,67 2,70 $ 57.672 156 T
  03.07.12      2,66      2,74§2,64 2,70 $ 16.221 43.630
  02.07.12      2,59      2,71§2,57 2,64 $ 72.807 194 T  

wird gehandelt nur gibt sich keiner erkenntlich wenn einer eine Order aufgibt,alles was hier geschieht geschieht nur personal geistesgegenwärtig am PC
ordern abordern Kasse zählen  

hat Kiel gleich doppelt reinkopiert

das hier

http://www.ariva.de/news/...d-from-Abbott-Health-Care-Pvt-Ltd-4183304  

SKP Platz Frankfurt: +2,13% *freu*  

14:06 25.07.12

PR Newswire

ALBANY, N.Y., July 25, 2012

ALBANY, N.Y., July 25, 2012 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced it will issue second quarter financial results before the opening of the market on Wednesday, August 1, 2012.  Following the release of its results, the company will host a conference call and simultaneous webcast at 10 a.m. ET.

(Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO )

The conference call can be accessed by dialing 888-417-8462 (domestic calls) or 719-325-2450 (international calls) at 9:45 a.m. ET and entering passcode 7242377.  The webcast will be available live via the Internet and can be accessed on the company's website at www.amriglobal.com.  Replays of the webcast can also be accessed for up to 90 days after the call via the investor area of the company's website at www.amriglobal.com/investor_relations/.

About AMRI

Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development, and manufacturing services. For over 21 years AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development.

SOURCE AMRI
Quelle: PR Newswire  

>>>>60.659  

http://www.ariva.de/news/...unces-Second-Quarter-2012-Results-4201885

MfG Buran  

spread beachten!  

wer kennt das nicht - das klingt doch -welch Ausdruck
.....+0,67% immer wieder die 3 Dollar,die sollten als Sprungbrett genutzt werden und halten,weiterhin vile Freude auf Schloss Albany ;-) kleines Spässle muss immer sein,gelle  

und immer wenn eine Sturmflut herrscht dürfen sich ihre Münder hochoben auf der Burg berühren und ihre Schatten für eine Nacht lang tanzen......bbbboa da krieg ich jedesmal Gänsehaut(Guido Hoffman glaube ich #16 Roger Whittaker)
__________________________________________________
und der aktuelle Ticker,büdde:
Nasdaq 2,98  $ 0,00% 2,98 $ 100 36.301 2,93 -  3,0099 20:25:04  

gestern tageshoch von fetten 3,3501 in Dollar *grinz*  

Branche sonstige
  HerkunftUSA
Indizes/Listen NASDAQ          §
Aktienanzahl§30,8 Mio. (Stand: 11.08.12)
 Marktkap.§80,3 Mio. €  

at Rodman & Renshaw Annual Global Investment Conference

14:00 31.08.12

PR Newswire

ALBANY, N.Y., Aug. 31, 2012

ALBANY, N.Y., Aug. 31, 2012 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that AMRI Chairman, President and Chief Executive Officer Thomas E. D'Ambra, Ph.D. will present at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 10, 2012 at 3:15 p.m. ET.

(Logo:  http://photos.prnewswire.com/prnh/20120229/NY61160LOGO)

A webcast of the corporate presentation will be available to investors and interested parties by accessing the company's website at www.amriglobal.com. This webcast will be archived for 90 days following the live presentation.

About AMRI

Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development, and manufacturing services. For over 21 years AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development.  

SOURCE AMRI
Quelle: PR Newswire  

"Quelle: PR Newswire" ist echt klasse,soweit ich weiss ist das Analystenhaus noch nicht lange im Geschäft,also auf dem Markt,aber top Leistung.Danke und weiter si Jungs!

Buran  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  05.09.12      3,28      3,34§3,24 3,30 $ 17.775 59 T  

weil wir's drauf haben,da geht noch was da kommt noch was,wir warten auf anstehende news,vielleicht gar Börsen-news-letter.......spannend ;-)  

Chief Financial Officer and Treasurer

13:35 12.09.12

PR Newswire

ALBANY, N.Y., Sept. 12, 2012

ALBANY, N.Y., Sept. 12, 2012 /PRNewswire/ -- Albany Molecular Research Inc. (Nasdaq: AMRI) today announced the appointment of Michael Nolan as Vice President, Chief Financial Officer and Treasurer of AMRI, succeeding Mark Frost, effective September 17, 2012.

(Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO )

Mr. Nolan was most recently Vice President, Finance, Financial Planning and Analysis at the Delaware North Companies, headquartered in Buffalo, N.Y. From 2009 through early 2012, Mr. Nolan was Vice President, Finance, Analytical Instruments Group at Thermo Fisher Scientific, Inc. where he was responsible for the global financial operations of a portfolio with revenue of $3 billion operating across three divisions with 15 business units, 41 plant sites and 9,700 employees. Prior to Thermo Fisher Scientific, Mr. Nolan held positions of increasing responsibility at ALCAN, which was later acquired by Rio Tinto Plc. While at Rio Tinto Plc., Mr. Nolan was accountable for leading the integration of 13 global ALCAN and Rio Tinto Plc. functions, including legal, company secretarial, business development and all finance functions including both the corporate and business teams. Mr. Nolan began his career in 1989 at E.I. du Pont de Nemours Company and received his MBA from The University of Windsor and a B.A. in Economics from The University of Western Ontario.

"I would like to thank Mark for his considerable contributions to AMRI in the almost eight years he has spent with the Company," said Thomas D'Ambra, Ph.D., AMRI's Chairman, President and Chief Executive Officer. "He was instrumental in building the Company's global reach as we expanded through both acquisitions and internal growth during his tenure. We wish him well in all his future endeavors and have established a plan to ensure a seamless transition to our new CFO."

D'Ambra continued, "The Board of Directors and I are pleased to welcome Mike to AMRI. He has had considerable experience in the business of science as well as overseeing the operational and finance requirements of a global business. We have made solid progress in reducing our cost structure, and increasing our marketing efforts as we roll out our new SMARTSOURCING™ initiative. Mike's strategic leadership, financial expertise and strong global experience will further support these initiatives and help us realize our plan for future growth and profitability."

About AMRI  

Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development, and manufacturing services. For over 21 years AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For press releases and additional information about the company, please visit www.amriglobal.com.

SOURCE AMRI
Quelle: PR Newswire  

at UBS Global Life Sciences Conference

14:05 13.09.12

PR Newswire

ALBANY, N.Y., Sept. 13, 2012

ALBANY, N.Y., Sept. 13, 2012 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that AMRI Chairman, President and Chief Executive Officer Thomas E. D'Ambra, Ph.D. will present at the UBS Global Life Sciences Conference on Thursday, September 20, 2012 at 4:30 p.m. ET.

(Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO )

A webcast of the corporate presentation will be available to investors and interested parties by accessing the company's website at www.amriglobal.com. This webcast will be archived for 90 days following the live presentation.

About AMRI

Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development, and manufacturing services. For over 21 years AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCINGTM, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development.  

SOURCE AMRI
Quelle: PR Newswire